266 related articles for article (PubMed ID: 24468835)
21. [Graft versus host disease and cytokines].
Itoh T
Nihon Rinsho; 2003 Sep; 61(9):1504-11. PubMed ID: 14515716
[TBL] [Abstract][Full Text] [Related]
22. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
23. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
24. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
25. The role of JAK inhibitors in hematopoietic cell transplantation.
Salit RB
Bone Marrow Transplant; 2022 Jun; 57(6):857-865. PubMed ID: 35388118
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
27. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
[TBL] [Abstract][Full Text] [Related]
28. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
[TBL] [Abstract][Full Text] [Related]
29. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.
Gu G; Yang JZ; Zhang JQ; Sun LX
Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390
[TBL] [Abstract][Full Text] [Related]
30. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
31. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
Jiang H; Fu D; Bidgoli A; Paczesny S
Front Immunol; 2021; 12():761448. PubMed ID: 34675938
[TBL] [Abstract][Full Text] [Related]
32. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
[TBL] [Abstract][Full Text] [Related]
33. Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.
Chen S; Zeiser R
Front Immunol; 2020; 11():1854. PubMed ID: 33013836
[TBL] [Abstract][Full Text] [Related]
34. NK cell predicts the severity of acute graft-versus-host disease in patients after allogeneic stem cell transplantation using antithymocyte globulin (ATG) in pretreatment scheme.
Zhang P; Yang S; Zou Y; Yan X; Wu H; Zhou M; Sun YC; Zhang Y; Zhu H; Xu K; Wang Y; Sheng LX; Mu Q; Sun L; Ouyang G
BMC Immunol; 2019 Dec; 20(1):46. PubMed ID: 31818250
[TBL] [Abstract][Full Text] [Related]
35. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
36. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
Park JH; Lee HJ; Kim SR; Song GW; Lee SK; Park SY; Kim KC; Hwang SH; Park JS
Korean J Intern Med; 2014 Sep; 29(5):630-6. PubMed ID: 25228839
[TBL] [Abstract][Full Text] [Related]
37. Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies.
Akpinar S; Kayikci O; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103367. PubMed ID: 35120825
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
39. [Recent advances in pathophysiology, diagnosis and treatment of steroid-refractory graft-versus-host disease].
Toubai T; Torii Y
Rinsho Ketsueki; 2021; 62(11):1557-1566. PubMed ID: 34866077
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
Carnevale-Schianca F; Leisenring W; Martin PJ; Furlong T; Schoch G; Anasetti C; Appelbaum FR; Carpenter PA; Deeg HJ; Kiem HP; Storb R; McDonald GB; Nash RA
Biol Blood Marrow Transplant; 2009 Jun; 15(6):749-56. PubMed ID: 19450760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
